GF Fund Management CO. LTD. Invests $637,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

GF Fund Management CO. LTD. bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,708 shares of the biopharmaceutical company's stock, valued at approximately $637,000.

Other institutional investors have also recently made changes to their positions in the company. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $1,045,822,000. Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $577,941,000. Capital Research Global Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in shares of Alnylam Pharmaceuticals by 496.6% in the fourth quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after acquiring an additional 315,182 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ALNY shares. Royal Bank of Canada upped their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Citigroup increased their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Stock Up 2.5%

Shares of NASDAQ ALNY traded up $7.23 during mid-day trading on Friday, reaching $300.13. 874,831 shares of the company were exchanged, compared to its average volume of 919,883. Alnylam Pharmaceuticals, Inc. has a 1 year low of $146.79 and a 1 year high of $304.39. The firm has a 50-day moving average of $259.91 and a 200 day moving average of $254.83. The stock has a market cap of $39.13 billion, a price-to-earnings ratio of -138.41 and a beta of 0.17. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same period last year, the firm posted ($0.16) earnings per share. The business's revenue was up 20.2% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.